# Prior notification of a concentration

## (Case M.9554 – Elanco Animal Health/Bayer Animal Health Division)

**(Text with EEA relevance)**

(2020/C 132/09)

1. On 14 April 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1].

This notification concerns the following undertakings:

— Elanco Animal Health Inc. (USA) ('Elanco'),

— Bayer AG's animal health business ('BAH'), controlled by Bayer AG (Germany) ('Bayer').

Elanco acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of BAH.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for Elanco: Elanco is an animal health company that develops, manufactures and markets products for companion and production animals worldwide,

— for BAH: BAH comprises Bayer's animal health business and is active in the development, production and marketing of products for companion and production animals worldwide.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9554 – Elanco Animal Health/Bayer Animal Health Division

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').